Search
for

    Did you mean Sustained Release?
    GlossarySustained Release

    drug delivery system releasing medication slowly over time

    Sustained Release (SR), also known as Extended Release (ER) or Controlled Release (CR), refers to a drug delivery system designed to release a medication slowly over time. This allows for a more consistent therapeutic effect, reduces the frequency of dosing, and can improve patient compliance by maintaining steadier drug levels in the bloodstream.

    Related Terms

    Learn

    1 / 1 results

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

    Research

    5 / 1000+ results

    Community Join

    5 / 87 results

      community Medications that cause extra hair growth

      in Research/Science  121 upvotes 11 months ago
      The post discusses the side effects of various drugs causing excess hair growth, questioning why only minoxidil is used in the hair loss industry. The conversation includes users sharing their experiences and concerns about potential side effects of these drugs, with some preferring baldness over potential health risks.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  43 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community Verteporfin and Microneedling

      in Treatments 3 months ago
      Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 5 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.